Phosphodiesterase Type 4 Inhibitors: Potential in the Treatment of Multiple Sclerosis?

ISSN： 1173-8804

Source： BioDrugs, Vol.13, Iss.2, 2000-02, pp. : 87-94

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies

Current Drug Therapy, Vol. 11, Iss. 1, 2016-04 ,pp. : 21-40

Bentham Science Publishers

Access to resources Recommend Favorite

Relapsing-Remitting Multiple Sclerosis: What is the Potential for Combination Therapy?

By Mäurer M. Rieckmann P.

BioDrugs, Vol. 13, Iss. 3, 2000-03 ,pp. : 149-158

Adis International

Access to resources Recommend Favorite

Anti-Interleukin-12 Antibody: Potential Role in Preventing Relapses of Multiple Sclerosis

By Fox R.J. Rostami A.M.

BioDrugs, Vol. 13, Iss. 4, 2000-04 ,pp. : 233-241

Adis International

Access to resources Recommend Favorite

Treatment of Secondary Progressive Multiple Sclerosis: Current Recommendations and Future Prospects

By Rice G.P.A.

BioDrugs, Vol. 12, Iss. 4, 1999-10 ,pp. : 267-277

Adis International

Access to resources Recommend Favorite

Treatment of Multiple Sclerosis with the Interferon- s: Comparative Risks and Benefits

By Herndon R.M.

BioDrugs, Vol. 10, Iss. 6, 1998-12 ,pp. : 463-470

Adis International

Access to resources Recommend Favorite